Click Here to return To Results

 

Oral Anticoagulants Versus Antiplatelet Therapy for Preventing Stroke in Patients With Nonvalvular Atrial Fibrillation and No History of Stroke or Transient Ischemic Attacks Stroke 39:1399-1400, Aguilar,M.I. &Hart,R., 2008 See this aricle in Pubmed Article Abstract Adjusted-dose warfarin and related oral vitamin K antagonists reduce stroke, disabling stroke and other major vascular events for those with nonvalvular AF by about one third when compared with antiplatelet therapy. Based on meta-analysis of other trials, antiplatelet agents reduce stroke by about 20% in AF patients compared with no therapy, offering a less efficacious therapeutic option for those deemed not eligible for anticoagulation therapy. Considering the results from all available relevant randomized trials, oral anticoagulants reduce stroke in AF patients more effectively than antiplatelet agents, reducing ischemic strokes by half and doubling the less frequent hemorrhagic strokes for an overall net reduction. The threshold of absolute benefit that warrants anticoagulation instead of antiplatelet therapy remains controversial and depends on patient�s preferences and availability of optimal anticoagulation monitoring.

Related Tags

(click to filter results - removes previous filter) anticoagulant,treatment anticoagulant,treatment in CVD atrial fibrillation cerebrovascular accident cerebrovascular accident,prevention of efficacy platelet inhibiting drugs prevention of neurologic disorders risk factors

Click Here to return To Results